Theranova, L.L.C.
14
2
3
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
7.1%
1 terminated/withdrawn out of 14 trials
88.9%
+2.4% vs industry average
0%
0 trials in Phase 3/4
63%
5 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
EMPOWER AUD Pivotal Trial
Role: lead
Pilot Study of the Entarik System With Advanced Functionality in Health Adults
Role: collaborator
Airway Data Collection With the Entarik Feeding Tube System
Role: lead
Empower Neuromodulation System - Pilot Study for Anxiety Treatment
Role: lead
Evaluation of the TheraNova Neuromodulation System for the Treatment of Overactive Bladder Symptoms
Role: lead
Evaluation of the TheraNova Neuromodulation System to Provide Durable Relief of Overactive Bladder Symptoms
Role: lead
Evaluation of the Spry Belt for Improving Bone Quality
Role: lead
Pilot Research on Opioid Use Disorder
Role: lead
Evaluation of Peripheral Nerve Stimulation for Acute Treatment of Migraine Pain
Role: lead
Posterior Tibial Nerve Stimulation's Effectiveness in UI Frequency in Overactive Patients in Home
Role: lead
Wearable Vibration Device to Prevent Bone Loss in Postmenopausal Women--Aim 2
Role: lead
Pilot Evaluation of the Empower Neuromodulation System in AUD Patients
Role: lead
Treatment Parameters for the Empower Neuromodulation System (ENS)
Role: lead
Comparing PA Compliance During and After Decompensation in HFP
Role: lead
All 14 trials loaded